DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Filgotinib
Filgotinib
WO 2018/223101 Al 06 December 2018 (06.12.2018) W !P O PCT
Gvhd
JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: a Focus on the Present and an Outlook on the Future
Study Protocol
Recommendations from York and Scarborough Medicines
Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
Jyseleca, INN-Filgotinib
Study Protocol
CHMP Agenda of the 19-22 April 2021 Meeting
Statistical Analysis Plan
The LEONARDO Study Final Report
Efficacy and Safety of Filgotinib, a Selective Janus Kinase 1 Inhibitor
Immunology Lecture Edinburgh
Initiation (Q1 2017 18)
Filgotinib for Moderate to Severe Rheumatoid Arthritis
WHO Drug Information Vol
Stembook 2018.Pdf
(CHMP) Agenda for the Meeting on 17-20 May 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes
Top View
NICE TA Adherence Checklist 2020/2021 ELHE
The JAK/STAT Signaling Pathway and Its Role in Immune-Mediated Inflammatory Disease: Impact on the Treatment of IBD
WHO-EMP-RHT-TSN-2018.1-Eng.Pdf
Nhs Southampton City/Nhs Hampshire/Southampton
Anti-CD3 Drug Keeps Diabetes At
RMD Commentary, JAK Kinase Inhibitors: a Preferred Alternative to TNF Inhibitors?
Translating Jaks to Jakinibs Massimo Gadina, Danielle A
2017 Annual Report
Gilead Sciences, Inc
ACP NH Annual Scientific Meeting-2019
Form 2400 R8 (Page 1 of 26)
The Jak1-Selective Inhibitor Filgotinib Reduces Multiple
CHMP Agenda of the 20-23 July 2020 Meeting
Downloaded from Chemaxon (Budapest, Hungary)[115,171-183]
Filgotinib Versus Placebo Or Adalimumab in Patients With
Drugs to Watch 2020 and Potential Drugs in Research on COVID-19
( 12 ) Patent Application Publication ( 10 ) Pub . No .: US 2019/0352271 A1
JAK Inhibitors and Monoclonal Antibodies for the Treatment of Atopic Dermatitis: Effectiveness and Value
Commissioned List of Indications 2021-2022
Health Plan Insights
Specialty Pipeline MONTHLY UPDATE
Patient Information and Informed Consent Form
A Journey Through Anti-Inflammatory Drug Discovery
Press Release
Mechanisms of Action of Emerging Agents in GVHD
TYK2 in Cancer Metastases: Genomic and Proteomic Discovery
A View Into Upcoming Specialty & Traditional Drugs
CHMP Agenda of the 25-29 January 2021 Meeting
Filgotinib for Moderate to Severe Rheumatoid Arthritis 1 Recommendations
Evaluatepharma World Preview 2019, Outlook to 2024
CTRI Trial Data
October 2017 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
EFPIA Pipeline Review 2021 Update
Joint-Specific DNA Methylation and Transcriptome Signatures In
BMT CTN 2017 Progress Report
Filgotinib (GLPG0634/GS-6034), an Oral JAK1 Selective Inhibitor, Is
Review of Chromatographic Methods Coupled with Modern Detection Techniques Applied in the Therapeutic Drugs Monitoring (TDM)
Filgotinib for Moderate to Severe Active Rheumatoid Arthritis
Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease Pavine L
NICE Technology Appraisals About Medicines: Formulary Adherence
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
January 2018 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
Slide Presentation
March/April 2020 Health Care Professionals
Study Protocol
Publication Agenda CHMP 09-12 December 2019 CHMP
The JAK/STAT Signaling Pathway and Its Role in Immune-Mediated Inflammatory Disease: Impact on the Treatment of RA
CHMP Agenda of the 19-22 July 2021 Meeting